Hematology Department, Division of Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Bone Marrow Transplant. 2013 Jun;48(6):761-70. doi: 10.1038/bmt.2012.236. Epub 2012 Dec 3.
In this multicenter retrospective study, the long-term outcomes of 878 adults with AML and refractory anemia with excess blasts (RAEB) with BM blasts <10% who underwent transplantation with an HLA-identical sibling donor between 1998 and 2004 were analyzed according to four regimens of conditioning intensity: reduced-intensity conditioning (RIC) (either intermediate RIC (IntermRIC) or non-myeloablative (NMA) RIC), and myeloablative conditioning (MC) in 718 patients (either conventional MC or hyperintense MC. In multivariate cox analysis, patients undergoing NMA transplantation had lower non-relapse mortality risk in the first 100 days after transplantation (P<0.01), but a higher risk beyond day +100 (P=0.02), as well as higher relapse incidence in the first 12 months (P<0.01), but the risk was similar in all groups beyond 12 months. The probabilities of PFS and OS up to 7 years were significantly lower only in the NMA subgroup (P0.01 for both). The 7-year OS was 53%, 29%, 56% and 51%, respectively. Our data suggest that prospective studies comparing RIC regimens (especially IntermRIC) with MC are appropriate in patients with AML and RAEB who are in a non-advanced disease status.
在这项多中心回顾性研究中,分析了 1998 年至 2004 年间 878 例 AML 和骨髓原始细胞>10%但<20%的难治性贫血伴原始细胞增多(RAEB)患者接受 HLA 完全相合同胞供者移植的长期结果,根据四种预处理强度方案:低强度预处理(RIC)(中强度 RIC [IntermRIC]或非清髓性 RIC [NMA])和 718 例患者的清髓性预处理(MC)(常规 MC 或超强度 MC)。多因素 Cox 分析显示,NMA 移植患者在移植后 100 天内非复发死亡率较低(P<0.01),但在第 +100 天以后风险较高(P=0.02),12 个月内复发风险较高(P<0.01),但 12 个月后各组风险相似。在 NMA 亚组中,PFS 和 OS 概率直到 7 年显著降低(两者均 P<0.01)。7 年 OS 分别为 53%、29%、56%和 51%。我们的数据表明,在 AML 和 RAEB 患者处于非晚期疾病状态时,比较 RIC 方案(特别是 IntermRIC)与 MC 的前瞻性研究是合适的。